14 completed, 3 unknown, 2 withdrawn, 1 not yet recruiting. 20 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 14, Unknown 3, Withdrawn 2, Not yet recruiting 1 |
| Phase 2 | 7 | Completed 5, Not yet recruiting 1, Unknown 1 |
Follow Pyrimethamine: new trials by email Literature Review of Pyrimethamine trials Research Report on Pyrimethamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combining Latency Reversing Agents to Address the HIV Reservoir Pyrimethamine (PYR), Lenalidomide, Topiramate (drug) - HIV (Human Immunodeficiency Virus), HIV -1 Infection | Phase 1 / Phase 2 | Not yet recruiting | Erasmus Medical Center | 30 | 2026-04-01 | 2026-02-03 |
| Bioequivalence Study of Sulfadoxine/Pyrimethamine 500/25 mg Dispersible Tablet Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets., Sulfadoxine 500 MG / Pyrimethamine 25 MG dispersible tablets in SPAQ - Fasting | Phase 1 | Unknown | Swiss Pharma Nigeria Limited | 46 | 2024-07-01 | 2024-07-26 |
| Optimizing Reversal of HIV Latency With Combination Therapy Panobinostat 20 MG Oral Capsule, Pyrimethamine 200mg Oral Tablet, Lenalidomide 25 MG Oral Capsule - Hiv | Phase 1 / Phase 2 | Unknown | Erasmus Medical Center | 49 | 2024-04-01 | 2024-02-05 |
| Bioequivalence Study of Sulfadoxine/ Pyrimethamine Dispersible Tablets in Healthy Subjects Under Fasting Conditions Sulfadoxine/Pyrimethamine dispersible tablets, 250 mg sulfadoxine / 12.5 mg pyrimethamine & 500 mg sulfadoxine / 25 mg pyrimethamine, G-COSPE® tablets - Bioequivalence | Phase 1 | Unknown | Emzor Pharmaceutical Industries Limited | 70 | 2022-12-01 | 2022-08-11 |
| An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition. BMS-986165, Pyrimethamine - Healthy Male Volunteers | Phase 1 | Completed | Bristol-Myers Squibb | 16 | 2019-09-12 | 2020-08-05 |
| Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS) Pyrimethamine - Myelodysplastic Syndromes | Phase 1 | Withdrawn | Montefiore Medical Center | 2019-09-11 | 2021-09-22 | |
| Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa... Chloroquine Phosphate, PfSPZ Challenge, Pyrimethamine - Malaria | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 252 | 2019-05-23 | 2022-07-12 |
| LRAs United as a Novel Anti-HIV Strategy. Valproic Acid, Pyrimethamine - HIV-1-infection | Phase 1 / Phase 2 | Completed | Erasmus Medical Center | 28 | 2018-04-18 | 2021-04-29 |
| Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects Pyrimethamine, Calcium folinate - Toxoplasmosis | Phase 1 | Completed | GlaxoSmithKline | 14 | 2017-09-25 | 2020-03-27 |
| Dose Escalation PfSPZ-CVac Chloroquine Phosphate, Pyrimethamine, Sanaria PfSPZ Challenge - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 55 | 2017-06-05 | 2021-06-01 |
| Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B... Chloroquine (CQ), Pyrimethamine (PYR), Sanaria PfSPZ Challenge (NF54) - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 57 | 2015-07-21 | 2017-07-02 |
| Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction of Pyrimethamine and Metformin IR Metformin and Pyrimethamine - Healthy | Phase 1 | Completed | Seoul National University Hospital | 20 | 2013-06-01 | 2013-11-01 |
| Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma pyrimethamine - Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 20 | 2010-03-01 | 2023-02-22 |
| SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS) Pyrimethamine - Familial Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Completed | Weill Medical College of Cornell University | 32 | 2009-11-01 | 2017-06-19 |
| Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease) Pyrimethamine, Leucovorin - Gangliosidoses, GM2, Sandhoff Disease | Phase 1 / Phase 2 | Completed | The Hospital for Sick Children | 20 | 2009-08-01 | 2012-02-23 |
| A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis Pyrimethamine - G(M2) Ganglioside, Tay-Sachs Disease Ganglioside | Phase 1 | Withdrawn | Exsar Corporation | 2008-05-01 | 2013-02-25 | |
| Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome Pyrimethamine - Autoimmune Disease, Lymphatic Disease | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 8 | 2003-07-01 | 2008-03-04 |
| Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome Fansidar (pyrimethamine and sulfadoxine) - Autoimmune Disease, Lymphoproliferative Disorder | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 8 | 2001-03-01 | 2008-03-04 |
| A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients Pyrimethamine, Leucovorin calcium, Zidovudine - Toxoplasmosis, Cerebral, HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 26 | 2021-11-04 | |
| A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS Azithromycin, Pyrimethamine, Leucovorin calcium - Toxoplasmosis, Cerebral, HIV Infections | Phase 1 | Completed | Pfizer | 45 | 2008-08-26 |
Acquired Immunodeficiency Syndrome (3) · Malaria (3) · Toxoplasmosis (3) · Autoimmune Diseases (2) · Autoimmune Lymphoproliferative Syndrome (2) · Encephalitis (2) · Gangliosidoses, GM2 (2) · HIV Infections (2) · Lymphadenopathy (2) · Lymphoproliferative Disorders (2) · Recurrence (2) · Sandhoff Disease (2) · Splenomegaly (2) · Tay-Sachs Disease (2) · Toxoplasmosis, Cerebral (2)
National Institute of Allergy and Infectious Diseases (NIAID) (6) · Erasmus Medical Center (3) · Bristol-Myers Squibb (1) · Dana-Farber Cancer Institute (1) · Emzor Pharmaceutical Industries Limited (1) · Exsar Corporation (1) · GlaxoSmithKline (1) · Montefiore Medical Center (1) · Pfizer (1) · Seoul National University Hospital (1) · Swiss Pharma Nigeria Limited (1) · The Hospital for Sick Children (1) · Weill Medical College of Cornell University (1)
United States (11) · Netherlands (3) · Canada (2) · Australia (1) · Germany (1) · Italy (1) · Jordan (1) · Mali (1) · South Korea (1) · Sweden (1)
Casper Rokx, MD PhD (2) · Patrick E Duffy, M.D. (2) · Aditi Shastri, MD (1) · B Luft (1) · Bijan Almassian, Ph.D. (1) · Dale J. Lange, M.D. (1) · Jae-Yong Chung, MD, PhD (1) · Jennifer Brown, MD, PhD (1) · Joe T Clarke, MD (1) · Luft B (1) · Majdi Abu Awida, Doctor (1) · Remington J (1) · Sara A Healy, M.D. (1) · Tokameh Mahmoudi, PhD (1)
2017 (1), 2019 (1)